Clinical trials: Malaria, completed
Malaria, Falciparum
Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria
Chlorproguanil-dapsone has been approved for the treatment of uncomplicated Plasmodium falciparum malaria in a number of countries across sub-Sahara Africa, and by the UK's Medicines and Healthcare products Regulatory Agency.
- Trial name
- NCT00344006
- Testing
- chlorproguanil-dapsone-artesunate, artemether-lumefantrine
- Where
- 9 sites in Burkina Faso, Ghana and 3 more
- Volunteers
- 1,395 people
- Sponsor
- GlaxoSmithKline
Malaria
A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2
The purpose of this study is to assess the safety, immunogenicity and efficacy of the candidate malaria vaccines ChAdOx1 LS2 and MVA LS2. Healthy adult volunteers will be recruited and vaccinated in Oxford.
- Trial name
- NCT03203421
- Testing
- ChAdOx1 LS2, MVA LS2
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Falciparum Malaria (Uncomplicated)
A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)
A partially blinded randomised controlled non-inferiority trial comparing the efficacy, tolerability and safety of Triple ACTs artemether-lumefantrine + amodiaquine (AL+AQ) and artesunate- mefloquine+piperaquine (AS-MQ+PPQ) with…
- Trial name
- DeTACT-ASIA (NCT03939104)
- Testing
- Artemether-lumefantrine+amodiaquine, Artesunate-mefloquine+piperaquine
- Where
- 3 sites in Bangladesh, Cambodia
- Volunteers
- 103 people
- Sponsor
- University of Oxford
Malaria, Malaria Vaccines
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
GSK Biologicals in partnership with the Malaria Vaccine Initiative at PATH is developing a candidate malaria vaccine GSK 257049 for the routine immunization of infants and children living in malaria endemic areas.
- Trial name
- NCT00289185
- Testing
- RTS,S/AS02D, Engerix-B®, TETRActHib™
- Where
- Tanzania
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria,Falciparum, Gametocytes
Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2
This is a single-center, open label study. The primary aim of this project is to develop a controlled human malaria infection transmission model ("CHMI-trans") or "challenge model" to evaluate the capacity of vaccines, biologics…
- Conditions
- Malaria,Falciparum, Gametocytes, Controlled Human Malaria Infection, Transmission
- Trial name
- CHMI-trans2 (NCT03454048)
- Testing
- Piperaquine (low dose), Piperaquine (high dose), Sulfadoxine pyrimethamine
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Plasmodium Falciparum
Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy
The main goal of this study is to assess the efficacy of RTS,S/AS01E, a candidate vaccine against malaria caused by Plasmodium falciparum (P. falciparum), in adults positive for P.
- Trial name
- NCT04661579
- Testing
- Malaria Vaccine RTS,S/AS01E, Abhayrab rabies vaccine, Dihydroartemisinin-piperaquine (DHA/Pip)
- Where
- Kenya
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- PATH
Malaria
Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.
This trial will evaluate the safety, tolerability, and immunogenicity of PfSPZ Vaccine in healthy Equatoguinean adults, adolescents, children and infants who receive doses of 0.9x10^6, 1.8x10^6 or 2.7x10^6 PfSPZ Vaccine via…
- Trial name
- NCT02859350
- Testing
- PfSPZ Vaccine, PfSPZ Challenge (for CHMI), Normal Saline
- Where
- Equatorial Guinea
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
Malaria Survey in the Tak Province Refugee Camps
According to the World Malaria Report, there were significant decreases in the number of P.falciparum (PF) malaria cases worldwide in the past decade.
- Trial name
- NCT01902797
- Testing
- Questionnaire
- Where
- Thailand
- Volunteers
- 908 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum, Plasmodium Falciparum
Safety and Protective Efficacy of Pb(PfCS@UIS4)
In the underlying study, a genetically modified P. berghei parasite is used. P. berghei is one of the four Plasmodium species that causes malaria in rodents. The hypothesis is that immunization of humans with P.
- Conditions
- Malaria,Falciparum, Plasmodium Falciparum, Plasmodium Berghei, Controlled Human Malaria Infection (CHMI)
- Trial name
- PbVac (NCT03138096)
- Testing
- Pb(PfCS@UIS4)-infected mosquitoes, Challenge infection P. falciparum
- Where
- 2 sites in Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria
A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine
The primary objective is to estimate the relative bioavailability of fixed azithromycin / chloroquine combination tablets relative to co-administered individual tablets of azithromycin and chloroquine.
- Trial name
- AZCQ (NCT00844207)
- Testing
- Fixed combination of Azithromycin and Chloroquine, Azithromycin and Chloroquine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Malaria
LLIN Evaluation in Uganda Project
In Uganda, the National Malaria Control Division (NMCD) and implementing partners plan to deliver long-lasting insecticidal nets (LLINs) nationwide in 2020-21, through a mass distribution campaign supported by generous…
- Trial name
- LLINEUP2 (NCT04566510)
- Testing
- long lasting insecticidal nets with alpha-cypermethrin + pyriproxyfen (PPF LLIN, Royal Guard)), long lasting insecticidal nets with deltamethrin + piperonyl butoxide (PBO LLIN, PermaNet 3.0)), Social behaviour change communication
- Where
- Uganda
- Volunteers
- 32,895 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Plasmodium Falciparum Malaria
Artemisinin-resistant Malaria in Cambodia
Background: Artemisinin-based combination therapies (ACTs) are the first-line treatments for malaria. ACTs are highly effective, but malaria caused by the Plasmodium falciparum parasite is becoming resistant to some ACTs.
- Trial name
- NCT01736319
- Where
- Cambodia
- Volunteers
- 561 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Mosquito Repellent
Effect of a Combined Use of Mosquito Repellent and Insecticide Treated Net on Malaria in Ethiopia
The combined use of a mosquito repellent and long lasting insecticidal nets (LLINs) by household members would result in a 40% reduction in malaria prevalence compared with households that only use LLINs.
- Conditions
- Malaria, Mosquito Repellent, Long Lasting Insecticidal Nets
- Trial name
- NCT01160809
- Testing
- Mosquito repellent
- Where
- Ethiopia
- Volunteers
- 6,082 people, healthy volunteers welcome
- Sponsor
- Malaria Consortium, Ethiopia
Sickle Cell Anemia in Children, Malaria
Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia
Sickle Cell Anaemia (SCA) is an inherited disease that makes the body produce red blood cells with abnormal sickle-shaped cells. The sickle-shaped cells are rigid, not flexible and break up easily resulting in anaemia.
- Trial name
- CHEMCHA (NCT04844099)
- Testing
- Dihydroartemisinin Piperaquine
- Where
- 3 sites in Malawi, Uganda
- Volunteers
- 723 people
- Sponsor
- Liverpool School of Tropical Medicine
Falciparum Malaria
Study to Investigate the Induction of an Protective Immune Response to Malaria
The objective of the study is to induce a protective immune response against malaria in healthy human volunteers. The different parts of the immune response will then be studied.
- Trial name
- NCT00442377
- Testing
- exposure to malaria sporozoites
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Plasmodium Falciparum Malaria
Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria
The primary trial objective is to determine the clinically effective dose of orally administered pyronaridine/artesunate (Pyramax®, PA) with a 3:1 ratio to treat adults with acute, symptomatic, uncomplicated P.
- Trial name
- NCT01594931
- Testing
- pyronaridine/artesunate
- Where
- 6 sites in Cambodia, Indonesia and 4 more
- Volunteers
- 477 people
- Sponsor
- Medicines for Malaria Venture
Child Malnutrition, Infant Morbidity
Effectiveness of Nutritional Supplementation in Preventing Malnutrition in Children With Infection in Karamoja, Uganda
The purpose of this study is to determine whether 14 days nutritional supplementation with Ready to use therapeutic Food (RUTF) or micronutrients alone to children having an infection will prevent malnutrition and reduce the…
- Trial name
- MSF-nutcon03 (NCT01497236)
- Testing
- Dietary Supplement: Nutrition supplement with RUTF or MNP
- Where
- Uganda
- Volunteers
- 2,202 people, healthy volunteers welcome
- Sponsor
- Medecins Sans Frontieres, Spain
Malaria
Getting Malaria "Off the Back" of Women and Children in Western Uganda
This is a two-phase, mixed-methods pilot study of insecticide-treated lesus to reduce the incidence of P. falciparum malaria among infants in a rural area of western Uganda.
- Trial name
- NCT04102592
- Testing
- Permethrin-treated Lesu (baby wrap), Untreated Lesu (baby wrap)
- Where
- Uganda
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Plasmodium Falciparum Infection, Malaria
Anti-malaria MAb in Malian Children
The purpose of this study is to evaluate the safety and tolerability of onetime subcutaneous (SC) or intravenous (IV) administration of monoclonal antibody (MAb) L9LS in healthy Malian adults and one-time SC administration of…
- Trial name
- L9LS (NCT05304611)
- Testing
- L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection, L9LS (VRC-MALMAB0114-00-AB) intravenous injection
- Where
- 2 sites in Mali
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sepsis Newborn, Malaria
Immune Dysfunction in Newborn Sepsis
The aim of the project is to study neonatal immune dysfunction associated to the risk of newborn sepsis in a malaria endemic area in Benin.
- Conditions
- Sepsis Newborn, Malaria, Immune Responses
- Trial name
- RECIPAL (NCT03780712)
- Testing
- Non applicable
- Volunteers
- 585 people
- Sponsor
- BioMérieux
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.